What is the half-life of B7-33?
B7-33 has a reported half life of ~6 min in-vitro native; ~60 min lipidated (no in-vivo PK), given subcutaneous. That is why it is typically dosed once daily in animal models. A shorter half life means more frequent dosing to keep blood levels steady, a longer one lets you space doses further apart.
Quick facts
- Half-life: ~6 min in-vitro native; ~60 min lipidated (no in-vivo PK)
- Route: Subcutaneous
- Typical schedule: Once daily in animal models
- Cycle length: Pre-clinical, no human protocol
References
- B7-33, single-chain peptide derivative of relaxin retains anti-fibrotic activity without hemodynamic effects — Hossain MA et al., Chem Sci, 2016
- B7-33 replicates the vasoprotective functions of human relaxin-2 (serelaxin) — Marshall SA, O'Sullivan K, Ng HH, et al., European Journal of Pharmacology, 2017
- Single chain peptide agonists of relaxin receptors — Praveen P, Kocan M, Valkovic A, et al., Molecular and Cellular Endocrinology, 2019
Pepdex is an editorial reference, not medical advice. Peptides vary in legal and approval status by country, many are research compounds without full human safety data. Talk to a qualified clinician before starting anything.
More on B7-33
Last updated 2026-06-06.